Thursday, January 30, 2020

QualityStocksNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Receives SofPulse(R) Orders From Multiple Plastic Surgery Centers


Endonovo Therapeutics (OTCQB: ENDV) today announced that it has secured sales of SofPulse(R), the company’s FDA-Cleared, non-invasive device utilized for the reduction of postoperative pain and edema, to multiple plastic surgery centers. “SofPulse(R) main distribution model is marketing to major hospitals throughout the US and is beginning to be viewed as the standard of care for postoperative pain and edema reduction for numerous inpatient hospital procedures. With the expansion of our customer base and recent orders from numerous plastic surgery centers, SofPulse(R) demonstrates different applications for its use,” Endonovo Therapeutics CEO Alan Collier stated in the news release. “We are quickly becoming the go to pain and edema reduction option for many out-patient surgical procedures performed at ASC’s throughout the US. These centers provide patients with cosmetic and reconstructive procedures resulting in a need for postoperative pain management. Many of the plastic surgery centers have state-of-the-art surgical suites and recovery rooms equipped to hospital standards and we continue working with these centers and completing evaluations. Although in the nascent stages of expanding into fully certified office-based surgery centers, we recognize the large and growing market size allowing us to be well poised to capitalize on this opportunity.”

To view the full press release, visit http://ibn.fm/XFQEg

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of noninvasive wearable Electroceuticals(R) therapeutic devices. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders, including traumatic brain injury (“TBI”), acute concussions, post-concussion syndrome and multiple sclerosis. The Company’s noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company’s current portfolio of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The Company’s noninvasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. For more information, visit www.Endonovo.com.

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: